VSTM – Verastem, Inc.
Verastem, Inc.VSTM
$6.42Name : Verastem, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $352,773,856.00
EPSttm : -3.36
Verastem, Inc.
$6.42
3.88%$0.24Float Short %
27.4
Margin Of Safety %
Put/Call OI Ratio
0.1
EPS Next Q Diff
0.28
EPS Last/This Y
0.74
EPS This/Next Y
1.07
Price
6.41
Target Price
15.75
Analyst Recom
1
Performance Q
-8.29
Relative Volume
0.98
Beta
0.86
Ticker: VSTM
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-05-08 | VSTM | 6.94 | 0.08 | 0.04 | 16944 |
| 2025-05-09 | VSTM | 7.16 | 0.08 | 0.00 | 17272 |
| 2025-05-12 | VSTM | 7.28 | 0.06 | 0.02 | 21992 |
| 2025-05-13 | VSTM | 7.47 | 0.06 | 0.04 | 22448 |
| 2025-05-14 | VSTM | 7.12 | 0.06 | 0.06 | 22269 |
| 2025-05-15 | VSTM | 7.91 | 0.06 | 0.14 | 22519 |
| 2025-05-16 | VSTM | 7.6 | 0.07 | 0.02 | 23128 |
| 2025-05-19 | VSTM | 7.76 | 0.04 | 0.09 | 21579 |
| 2025-05-20 | VSTM | 8.04 | 0.05 | 0.35 | 22580 |
| 2025-05-21 | VSTM | 7.61 | 0.07 | 0.06 | 22990 |
| 2025-05-22 | VSTM | 7.48 | 0.06 | 0.17 | 24481 |
| 2025-05-23 | VSTM | 8.31 | 0.07 | 0.55 | 25058 |
| 2025-05-27 | VSTM | 8.49 | 0.08 | 0.03 | 25801 |
| 2025-05-28 | VSTM | 7.61 | 0.07 | 0.08 | 27169 |
| 2025-05-29 | VSTM | 7.76 | 0.07 | 0.03 | 29636 |
| 2025-05-30 | VSTM | 7.53 | 0.06 | 0.02 | 31683 |
| 2025-06-02 | VSTM | 6.02 | 0.06 | 0.08 | 34352 |
| 2025-06-03 | VSTM | 5.9 | 0.07 | 0.78 | 33801 |
| 2025-06-04 | VSTM | 6.16 | 0.09 | 1.41 | 34678 |
| 2025-06-05 | VSTM | 6.18 | 0.09 | 0.70 | 35001 |
| 2025-06-06 | VSTM | 6.41 | 0.10 | 0.63 | 35353 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-05-08 | VSTM | 6.93 | 20.9 | - | -2.79 |
| 2025-05-09 | VSTM | 7.18 | 20.9 | - | -2.79 |
| 2025-05-12 | VSTM | 7.29 | 20.9 | - | -2.79 |
| 2025-05-13 | VSTM | 7.46 | 20.9 | - | -2.79 |
| 2025-05-14 | VSTM | 7.13 | 20.9 | - | -2.79 |
| 2025-05-15 | VSTM | 7.93 | 20.9 | - | -2.79 |
| 2025-05-16 | VSTM | 7.60 | 20.9 | - | -2.79 |
| 2025-05-19 | VSTM | 7.75 | -1.6 | - | -2.79 |
| 2025-05-20 | VSTM | 8.03 | -1.6 | - | -2.79 |
| 2025-05-21 | VSTM | 7.61 | -1.6 | - | -2.79 |
| 2025-05-22 | VSTM | 7.48 | -1.6 | - | -2.79 |
| 2025-05-23 | VSTM | 8.33 | -1.6 | - | -2.79 |
| 2025-05-27 | VSTM | 8.52 | -1.6 | - | -2.60 |
| 2025-05-28 | VSTM | 7.61 | -1.6 | - | -2.60 |
| 2025-05-29 | VSTM | 7.76 | -1.6 | - | -2.60 |
| 2025-05-30 | VSTM | 7.52 | -1.6 | - | -2.60 |
| 2025-06-02 | VSTM | 6.02 | -1.6 | - | -2.60 |
| 2025-06-03 | VSTM | 5.90 | -1.6 | - | -2.60 |
| 2025-06-04 | VSTM | 6.16 | -1.6 | - | -2.60 |
| 2025-06-05 | VSTM | 6.18 | -1.6 | - | -2.60 |
| 2025-06-06 | VSTM | 6.41 | -1.6 | - | -2.92 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-05-08 | VSTM | -0.26 | 49.44 | 18.99 |
| 2025-05-09 | VSTM | -0.26 | 49.44 | 18.99 |
| 2025-05-12 | VSTM | -0.23 | 21.71 | 20.43 |
| 2025-05-13 | VSTM | -0.23 | 21.71 | 20.43 |
| 2025-05-14 | VSTM | -0.23 | 21.71 | 20.43 |
| 2025-05-15 | VSTM | -0.23 | 21.71 | 20.43 |
| 2025-05-16 | VSTM | -0.21 | 21.71 | 19.14 |
| 2025-05-19 | VSTM | -0.21 | 28.91 | 19.00 |
| 2025-05-20 | VSTM | -0.23 | 28.91 | 19.00 |
| 2025-05-21 | VSTM | -1.39 | 28.91 | 19.00 |
| 2025-05-22 | VSTM | -1.39 | 28.91 | 19.00 |
| 2025-05-23 | VSTM | -1.39 | 28.91 | 19.00 |
| 2025-05-27 | VSTM | -1.28 | 15.98 | 19.20 |
| 2025-05-28 | VSTM | -1.28 | 15.98 | 27.36 |
| 2025-05-29 | VSTM | -1.28 | 15.98 | 27.36 |
| 2025-05-30 | VSTM | -1.28 | 15.98 | 27.36 |
| 2025-06-02 | VSTM | -1.27 | 16.21 | 27.40 |
| 2025-06-03 | VSTM | -1.27 | 16.21 | 27.40 |
| 2025-06-04 | VSTM | -1.27 | 16.21 | 27.40 |
| 2025-06-05 | VSTM | -1.27 | 16.21 | 27.40 |
| 2025-06-06 | VSTM | -1.27 | 16.21 | 27.40 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.96
Avg. EPS Est. Current Quarter
-0.77
Avg. EPS Est. Next Quarter
-0.68
Insider Transactions
-1.27
Institutional Transactions
16.21
Beta
0.86
Average Sales Estimate Current Quarter
6
Average Sales Estimate Next Quarter
5
Fair Value
Quality Score
6
Growth Score
37
Sentiment Score
45
Actual DrawDown %
89.2
Max Drawdown 5-Year %
-96.2
Target Price
15.75
P/E
Forward P/E
PEG
P/S
35.28
P/B
P/Free Cash Flow
EPS
-3.19
Average EPS Est. Cur. Y
-2.92
EPS Next Y. (Est.)
-1.85
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-1488.76
Relative Volume
0.98
Return on Equity vs Sector %
435
Return on Equity vs Industry %
453
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.57
EBIT Estimation
Verastem, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 78
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
stock quote shares VSTM – Verastem, Inc. Stock Price stock today
news today VSTM – Verastem, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VSTM – Verastem, Inc. yahoo finance google finance
stock history VSTM – Verastem, Inc. invest stock market
stock prices VSTM premarket after hours
ticker VSTM fair value insiders trading